We are live on ! Find out more
EDIT icon

Editas Medicine

215 hedge funds and large institutions have $1.15B invested in Editas Medicine in 2018 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 73 increasing their positions, 56 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 25

49% more call options, than puts

Call options by funds: $40.4M | Put options by funds: $27.1M

30% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 56

11% more capital invested

Capital invested by funds: $1.03B → $1.15B (+$119M)

9% more funds holding

Funds holding: 197215 (+18)

1.62% more ownership

Funds ownership: 66.44%68.05% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
215
Holders Change
+18
Holders Change %
+9.14%
% of All Funds
4.92%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
46
Increased
73
Reduced
56
Closed
25
Calls
$40.4M
Puts
$27.1M
Net Calls
+$13.2M
Net Calls Change
+$651K
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
126
Cypress Asset Management
Texas
$250K -$1.42K -40 -0.6%
AB
127
Amalgamated Bank
New York
$249K +$246K +6,951 New
Teacher Retirement System of Texas
128
Teacher Retirement System of Texas
Texas
$247K +$244K +6,902 New
SPC
129
Sigma Planning Corp
Michigan
$233K -$1.52K -43 -0.7%
PWM
130
Perigon Wealth Management
California
$232K +$229K +6,476 New
GKWIM
131
Gerber Kawasaki Wealth & Investment Management
California
$229K
XK
132
Xact Kapitalforvaltning
Sweden
$226K +$223K +6,300 New
ECM
133
Element Capital Management
New York
$218K +$850 +24 +0.4%
TCM
134
Telos Capital Management
California
$203K +$200K +5,655 New
RMCM
135
Reynders McVeigh Capital Management
Massachusetts
$202K +$200K +5,650 New
Cambridge Investment Research Advisors
136
Cambridge Investment Research Advisors
Iowa
$200K -$22.9K -646 -10%
NIT
137
NumerixS Investment Technologies
British Columbia, Canada
$179K -$21.2K -599 -11%
ADL
138
Asset Dedication LLC
California
$161K +$156K +4,400 +4,400%
AIP
139
Ameritas Investment Partners
Nebraska
$129K +$22.4K +634 +21%
CG
140
Cutler Group
California
$112K -$297K -8,400 -73%
SG Americas Securities
141
SG Americas Securities
New York
$111K -$245K -6,919 -69%
BFEC
142
Benjamin F. Edwards & Company
Missouri
$111K +$2.3K +65 +2%
FAM
143
Fortaleza Asset Management
Illinois
$107K -$47.4K -1,340 -31%
Zurich Cantonal Bank
144
Zurich Cantonal Bank
Switzerland
$92K
Walleye Trading
145
Walleye Trading
New York
$88K -$540K -15,259 -86%
BNP Paribas Financial Markets
146
BNP Paribas Financial Markets
France
$81.8K -$192K -5,427 -70%
TDC
147
Thompson Davis & Co
Virginia
$72K +$22.1K +625 +45%
Bank of Montreal
148
Bank of Montreal
Ontario, Canada
$61K +$34K +959 +131%
KBC Group
149
KBC Group
Belgium
$57K
WAM
150
Wealthspire Advisors (Maryland)
Maryland
$56K

EDIT Hedge Fund Activity: Q2 2018 in Review

215 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2018, worth a combined $1.15B — up 11% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new EDIT positions and 25 closed out — a net gain of 21 holders — while 73 added to existing stakes and 56 trimmed.

The largest buyer was BlackRock, adding an estimated $20.9M. The largest seller was Fidelity Investments, cutting an estimated $40.7M.

  • 215 institutional investors held Editas Medicine (EDIT) as of Q2 2018, up from 197 in Q1 2018.
  • Funds reported $1.15B of Editas Medicine stock for Q2 2018, up 11% quarter-over-quarter.
  • 46 funds opened new Editas Medicine positions in Q2 2018 and 25 closed out, a net change of +21 holders.
  • The largest Editas Medicine buyer in Q2 2018 was BlackRock, an estimated $20.9M added.
  • The largest Editas Medicine seller in Q2 2018 was Fidelity Investments, an estimated $40.7M sold.

Based on aggregated 13F filings for Q2 2018.